摘要
目的:比较吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的缓解率、一年生存率与毒性反应。方法:检索Pubmed数据库和CHKD数据库,纳入随机对照试验,用专用软件Review Manager version 4.2.2进行系统评价。结果:共有8个研究1741例患者纳入系统评价,吉西他滨+顺铂方案与长春瑞滨+顺铂方案在总缓解率和一年生存率上无区别,吉西他滨+顺铂方案中性粒细胞减少发生率低于长春瑞滨+顺铂方案,血小板减少发生率高于长春瑞滨+顺铂方案,恶心呕吐发生率与神经系统反应两者差异无统计学意义。结论:在晚期非小细胞肺癌治疗中,吉西他滨联合顺铂与长春瑞滨联合顺铂疗效相似,在毒性反应方面各有利弊,应结合患者具体情况,选择对患者生活质量影响较小的方案。
Objective： To compare and evaluate the effectiveness bine combined with cisplatin of advanced non-small cell lung cancer.1 -year survival rate and toxicities of gemcitabine versus vinorel- Method： Pubmed database and CHKD database were searched, included in randomized controlled trials, special software Review Manager version 4.2.2 was used of meta-analysis for systematic reviews. Result： Eight studies involving 1 741 patients were included. There was no different in the overall response and 1-year survival rate from gemeitabine versus vinorelbine in combination with eisplatin. The incidence rate of neutropenia was higher in vinorelbine ＋ cisplatin, and the thrombocytopenia was higher in gemcitabine ＋ cisplatin, nausea and vomiting and nervous system response was no significant difference between the two groups. Conclusion ： In advanced non-small cell lung cancer patients, gemcitabine plus cisplatin and vinorelbine combined with cisplatin is similar to efficacy and the toxic reactions have their own advantages and disadvantages.
出处
《中国药师》
CAS
2010年第5期638-641,共4页
China Pharmacist
基金
上海医院药学科研基金(编号:2008-YY-0225)
